ArticleiScience2026
Dual BAFF and APRIL inhibition with TACI-Fc depletes IgA plasma cells and ameliorates lupus nephritis.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
B cell activating factor (BAFF) and APRIL play an important role in driving systemic lupus erythematosus (SLE) immunopathogenesis and kidney damage in lupus nephritis (LN); however, the underlying immune mechanisms contributing to disease pathology are poorly understood. To investigate molecular profiles during the progression of LN, we carried out gene expression analysis on kidneys and spleens from lupus-prone NZM2328 mice treated for 4 weeks from the time of disease onset with BAFF and BAFF/APRIL inhibitors. Inhibition of BAFF alone had a limited impact on gene expression profiles of diseased mice. However, targeting both BAFF and APRIL through competitive inhibition with a transmembrane activator and CAML interactor (TACI)-Fc fusion protein significantly altered immune populations in the spleen, depleted IgA plasma cells, and also decreased inflammation in the kidneys of diseased mice. The impact of targeting both members of the BAFF family of cytokines in lupus-prone NZM2328 mice provides support for its application in the treatment of human LN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.